Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CASTLE BIOSCIENCES INCCSTL · Entity 359 | Director | June 17, 2021 | June 21, 2021 |
| NextCure, Inc.NXTC · Entity 7461 | Director | June 18, 2026 | June 22, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CASTLE BIOSCIENCES INC
Report date June 17, 2021 · Filed June 21, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy L.P. | 503,577 |
Reported balance
After 2021-06-17 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2021-06-17 · Sale · Disposed 30,000 · Balance 503,577 F1: The transaction on this Form 4 was made pursuant to a Rule 10b5-1 plan adopted by Sofinnova HealthQuest Partners, L.P. on December 17, 2020. F2: This transaction was executed in multiple trades at prices ranging from $75.0453 to $75.0922, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F3: Held by Sofinnova HealthQuest Partners, L.P., or HealthQuest Partners. HealthQuest Venture Management, L.L.C., or HealthQuest Management, is the general partner of HealthQuest Partners. David Kabakoff, Ph.D., the Reporting Person, is a partner of HealthQuest Management. Garheng Kong is the managing member of HealthQuest Management and has sole voting and investment power over the shares held by HealthQuest Partners. Each of HealthQuest Management, Mr. Kong and Dr. Kabakoff disclaims beneficial ownership over all shares held by HealthQuest Partners except to the extent of any pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: The transaction on this Form 4 was made pursuant to a Rule 10b5-1 plan adopted by Sofinnova HealthQuest Partners, L.P. on December 17, 2020.
F2: This transaction was executed in multiple trades at prices ranging from $75.0453 to $75.0922, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F3: Held by Sofinnova HealthQuest Partners, L.P., or HealthQuest Partners. HealthQuest Venture Management, L.L.C., or HealthQuest Management, is the general partner of HealthQuest Partners. David Kabakoff, Ph.D., the Reporting Person, is a partner of HealthQuest Management. Garheng Kong is the managing member of HealthQuest Management and has sole voting and investment power over the shares held by HealthQuest Partners. Each of HealthQuest Management, Mr. Kong and Dr. Kabakoff disclaims beneficial ownership over all shares held by HealthQuest Partners except to the extent of any pecuniary interest therein.
NextCure, Inc.
Report date June 18, 2026 · Filed June 22, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.02 · Expires 2036-06-17 | Direct | 3,510 |
Reported balance
After 2026-06-18 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-18 · Grant · Acquired 3,510 · Balance 3,510 F1: The option vests in full on the earlier of June 18, 2027 and the date of the 2027 Annual Meeting of Stockholders. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests in full on the earlier of June 18, 2027 and the date of the 2027 Annual Meeting of Stockholders.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 29, 2019 Filed Jul 31, 2019 22:48 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | ConversionSeries E-3 Preferred Stock · Derivative | 388,669 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-043912 · doc4.xml · derivative · entry 8 KABAKOFF DAVID S · CIK 0001024008 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By L.P. Disclosed balance after: 0 Underlying: Common Stock · 318,842 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Every 1.219 outstanding shares of Preferred Stock automatically converted into 1 share of Common Stock immediately prior to the closing of the Issuer's initial public offering (the "IPO"), for no additional consideration, with cash paid for any fractional shares. The Preferred Stock had no expiration date. F2 · price: Every 1.219 outstanding shares of Preferred Stock automatically converted into 1 share of Common Stock immediately prior to the closing of the Issuer's initial public offering (the "IPO"), for no additional consideration, with cash paid for any fractional shares. The Preferred Stock had no expiration date. F2 · derivative.exercise_date: Every 1.219 outstanding shares of Preferred Stock automatically converted into 1 share of Common Stock immediately prior to the closing of the Issuer's initial public offering (the "IPO"), for no additional consideration, with cash paid for any fractional shares. The Preferred Stock had no expiration date. F2 · derivative.expiration_date: Every 1.219 outstanding shares of Preferred Stock automatically converted into 1 share of Common Stock immediately prior to the closing of the Issuer's initial public offering (the "IPO"), for no additional consideration, with cash paid for any fractional shares. The Preferred Stock had no expiration date. F3 · ownership.nature: Held by Sofinnova HealthQuest Partners, L.P., or HealthQuest Partners. HealthQuest Venture Management, L.L.C., or HealthQuest Management, is the managing member of HealthQuest Partners. David Kabakoff, Ph.D., the Reporting Person, is a partner of HealthQuest Management. Garheng Kong is the managing member of HealthQuest Management and has sole voting and investment power over the shares held by HealthQuest Partners. Each of HealthQuest Management, Mr. Kong and Dr. Kabakoff disclaims beneficial ownership over all shares held by HealthQuest Partners except to the extent of any pecuniary interest therein. Read SEC document |
| July 29, 2019 Filed Jul 31, 2019 22:48 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | ConversionSeries E-2 Preferred Stock · Derivative | 436,910 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-043912 · doc4.xml · derivative · entry 7 KABAKOFF DAVID S · CIK 0001024008 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By L.P. Disclosed balance after: 0 Underlying: Common Stock · 358,416 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Every 1.219 outstanding shares of Preferred Stock automatically converted into 1 share of Common Stock immediately prior to the closing of the Issuer's initial public offering (the "IPO"), for no additional consideration, with cash paid for any fractional shares. The Preferred Stock had no expiration date. F2 · price: Every 1.219 outstanding shares of Preferred Stock automatically converted into 1 share of Common Stock immediately prior to the closing of the Issuer's initial public offering (the "IPO"), for no additional consideration, with cash paid for any fractional shares. The Preferred Stock had no expiration date. F2 · derivative.exercise_date: Every 1.219 outstanding shares of Preferred Stock automatically converted into 1 share of Common Stock immediately prior to the closing of the Issuer's initial public offering (the "IPO"), for no additional consideration, with cash paid for any fractional shares. The Preferred Stock had no expiration date. F2 · derivative.expiration_date: Every 1.219 outstanding shares of Preferred Stock automatically converted into 1 share of Common Stock immediately prior to the closing of the Issuer's initial public offering (the "IPO"), for no additional consideration, with cash paid for any fractional shares. The Preferred Stock had no expiration date. F3 · ownership.nature: Held by Sofinnova HealthQuest Partners, L.P., or HealthQuest Partners. HealthQuest Venture Management, L.L.C., or HealthQuest Management, is the managing member of HealthQuest Partners. David Kabakoff, Ph.D., the Reporting Person, is a partner of HealthQuest Management. Garheng Kong is the managing member of HealthQuest Management and has sole voting and investment power over the shares held by HealthQuest Partners. Each of HealthQuest Management, Mr. Kong and Dr. Kabakoff disclaims beneficial ownership over all shares held by HealthQuest Partners except to the extent of any pecuniary interest therein. Read SEC document |
| July 29, 2019 Filed Jul 31, 2019 22:48 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | ConversionSeries A Preferred Stock · Derivative | 19,524 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-043912 · doc4.xml · derivative · entry 6 KABAKOFF DAVID S · CIK 0001024008 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By L.P. Disclosed balance after: 0 Underlying: Common Stock · 16,015 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Every 1.219 outstanding shares of Preferred Stock automatically converted into 1 share of Common Stock immediately prior to the closing of the Issuer's initial public offering (the "IPO"), for no additional consideration, with cash paid for any fractional shares. The Preferred Stock had no expiration date. F2 · price: Every 1.219 outstanding shares of Preferred Stock automatically converted into 1 share of Common Stock immediately prior to the closing of the Issuer's initial public offering (the "IPO"), for no additional consideration, with cash paid for any fractional shares. The Preferred Stock had no expiration date. F2 · derivative.exercise_date: Every 1.219 outstanding shares of Preferred Stock automatically converted into 1 share of Common Stock immediately prior to the closing of the Issuer's initial public offering (the "IPO"), for no additional consideration, with cash paid for any fractional shares. The Preferred Stock had no expiration date. F2 · derivative.expiration_date: Every 1.219 outstanding shares of Preferred Stock automatically converted into 1 share of Common Stock immediately prior to the closing of the Issuer's initial public offering (the "IPO"), for no additional consideration, with cash paid for any fractional shares. The Preferred Stock had no expiration date. F3 · ownership.nature: Held by Sofinnova HealthQuest Partners, L.P., or HealthQuest Partners. HealthQuest Venture Management, L.L.C., or HealthQuest Management, is the managing member of HealthQuest Partners. David Kabakoff, Ph.D., the Reporting Person, is a partner of HealthQuest Management. Garheng Kong is the managing member of HealthQuest Management and has sole voting and investment power over the shares held by HealthQuest Partners. Each of HealthQuest Management, Mr. Kong and Dr. Kabakoff disclaims beneficial ownership over all shares held by HealthQuest Partners except to the extent of any pecuniary interest therein. Read SEC document |
| July 29, 2019 Filed Jul 31, 2019 22:48 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | PurchaseCommon Stock | 62,500 | $16.00 | $1,000,000.00 |
DisclosureSEC source: 0001209191-19-043912 · doc4.xml · nonDerivative · entry 5 KABAKOFF DAVID S · CIK 0001024008 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By L.P. Disclosed balance after: 1,833,577 F6 · shares: Represents a purchase from the underwriters in the Issuer's IPO. F3 · ownership.nature: Held by Sofinnova HealthQuest Partners, L.P., or HealthQuest Partners. HealthQuest Venture Management, L.L.C., or HealthQuest Management, is the managing member of HealthQuest Partners. David Kabakoff, Ph.D., the Reporting Person, is a partner of HealthQuest Management. Garheng Kong is the managing member of HealthQuest Management and has sole voting and investment power over the shares held by HealthQuest Partners. Each of HealthQuest Management, Mr. Kong and Dr. Kabakoff disclaims beneficial ownership over all shares held by HealthQuest Partners except to the extent of any pecuniary interest therein. Read SEC document |
| July 29, 2019 Filed Jul 31, 2019 22:48 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 9 | $16.00 | $144.00 |
DisclosureSEC source: 0001209191-19-043912 · doc4.xml · nonDerivative · entry 4 KABAKOFF DAVID S · CIK 0001024008 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By L.P. Disclosed balance after: 1,771,077 F5 · kind: On July 29, 2019, the reporting person exercised a warrant to purchase 11,572 shares of the Issuer's common stock for approximately $0.02 per share. The reporting person paid the exercise price on a cashless basis, resulting in the Issuer's withholding of 9 of the warrant shares to pay the exercise price and issuing to the reporting person the remaining 11,563 shares. F3 · ownership.nature: Held by Sofinnova HealthQuest Partners, L.P., or HealthQuest Partners. HealthQuest Venture Management, L.L.C., or HealthQuest Management, is the managing member of HealthQuest Partners. David Kabakoff, Ph.D., the Reporting Person, is a partner of HealthQuest Management. Garheng Kong is the managing member of HealthQuest Management and has sole voting and investment power over the shares held by HealthQuest Partners. Each of HealthQuest Management, Mr. Kong and Dr. Kabakoff disclaims beneficial ownership over all shares held by HealthQuest Partners except to the extent of any pecuniary interest therein. Read SEC document |
| July 29, 2019 Filed Jul 31, 2019 22:48 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | OtherCommon Stock | 11,572 | $0.02 | $231.44 |
DisclosureSEC source: 0001209191-19-043912 · doc4.xml · nonDerivative · entry 3 KABAKOFF DAVID S · CIK 0001024008 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By L.P. Disclosed balance after: 1,771,086 F3 · ownership.nature: Held by Sofinnova HealthQuest Partners, L.P., or HealthQuest Partners. HealthQuest Venture Management, L.L.C., or HealthQuest Management, is the managing member of HealthQuest Partners. David Kabakoff, Ph.D., the Reporting Person, is a partner of HealthQuest Management. Garheng Kong is the managing member of HealthQuest Management and has sole voting and investment power over the shares held by HealthQuest Partners. Each of HealthQuest Management, Mr. Kong and Dr. Kabakoff disclaims beneficial ownership over all shares held by HealthQuest Partners except to the extent of any pecuniary interest therein. Read SEC document |
| July 29, 2019 Filed Jul 31, 2019 22:48 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | ConversionCommon Stock | 83,453 | $12.80 | $1,068,198.40 |
DisclosureSEC source: 0001209191-19-043912 · doc4.xml · nonDerivative · entry 2 KABAKOFF DAVID S · CIK 0001024008 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By L.P. Disclosed balance after: 1,759,514 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · price: The principal amount of the Convertible Promissory Note held by HealthQuest Partners was $1,027,882. Upon closing of the IPO, all unpaid principal and accrued interest outstanding on the Convertible Promissory Note (the "Conversion Amount") automatically converted into the number of shares of Common Stock equal to the Conversion Amount as of the date immediately prior to the closing date divided by 80% of the IPO price per share of $16.00 per share. F3 · ownership.nature: Held by Sofinnova HealthQuest Partners, L.P., or HealthQuest Partners. HealthQuest Venture Management, L.L.C., or HealthQuest Management, is the managing member of HealthQuest Partners. David Kabakoff, Ph.D., the Reporting Person, is a partner of HealthQuest Management. Garheng Kong is the managing member of HealthQuest Management and has sole voting and investment power over the shares held by HealthQuest Partners. Each of HealthQuest Management, Mr. Kong and Dr. Kabakoff disclaims beneficial ownership over all shares held by HealthQuest Partners except to the extent of any pecuniary interest therein. Read SEC document |
| July 29, 2019 Filed Jul 31, 2019 22:48 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | ConversionCommon Stock | 1,676,061 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-043912 · doc4.xml · nonDerivative · entry 1 KABAKOFF DAVID S · CIK 0001024008 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By L.P. Disclosed balance after: 1,676,061 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The shares of Common Stock issued upon conversion of the Preferred Stock were calculated by first aggregating all series of Preferred Stock held by the Reporting Person, in accordance with the terms of the Company's then-effective Certificate of Incorporation. F2 · price: Every 1.219 outstanding shares of Preferred Stock automatically converted into 1 share of Common Stock immediately prior to the closing of the Issuer's initial public offering (the "IPO"), for no additional consideration, with cash paid for any fractional shares. The Preferred Stock had no expiration date. F3 · ownership.nature: Held by Sofinnova HealthQuest Partners, L.P., or HealthQuest Partners. HealthQuest Venture Management, L.L.C., or HealthQuest Management, is the managing member of HealthQuest Partners. David Kabakoff, Ph.D., the Reporting Person, is a partner of HealthQuest Management. Garheng Kong is the managing member of HealthQuest Management and has sole voting and investment power over the shares held by HealthQuest Partners. Each of HealthQuest Management, Mr. Kong and Dr. Kabakoff disclaims beneficial ownership over all shares held by HealthQuest Partners except to the extent of any pecuniary interest therein. Read SEC document |
| June 13, 2019 Filed Jun 18, 2019 00:23 UTC | NextCure, Inc. NXTC · Entity 7461 | GrantStock Option (Right to Buy) · Derivative | 22,000 | $0.00 Strike: $15.57 | $0.00 |
DisclosureSEC source: 0001123292-19-000892 · edgar.xml · derivative · entry 1 KABAKOFF DAVID S · CIK 0001024008 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,000 Underlying: Common Stock · 22,000 shares Expires 2029-06-12 F1 · derivative.exercise_date: The option vests in three equal annual installments beginning on June 13, 2020. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.